MIDLOTHIAN, Va., March 10 PARI's LC STAR nebulizer andPRONEB Ultra II compressor are the exclusive delivery devices for InspirePharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a potentialnew cystic fibrosis treatment. PARI reusable nebulizers are considered thegold standard for clinical trials and are recommended in commercial salesincluding AstraZeneca's Pulmicort Respules, Sepracor's Xopenex and Brovana,Novartis' TOBI, Genentech's Pulmozyme, and DEY LP's Accuneb, Duoneb, andPerforomist.
"PARI has a strong track record of reliable and efficient, reproducibledrug delivery, so it only makes sense that so many pharmaceutical companieslook to PARI when developing new medications," said Lisa Cambridge, directorof Clinical Development at PARI Respiratory Equipment. "Our LC STAR is a fineparticle nebulizer that enables delivery of aerosols to the smaller airways ofthe lungs -- beneficial for successful respiratory therapies."
Known as TIGER-2, Inspire's second pivotal Phase 3 clinical trial withdenufosol tetrasodium inhalation solution is beginning enrollment in the U.S.and Canada with patients age 5 years and older. The use of standard CFmaintenance therapies is permitted during the trial, and additionalinformation is available at http://www.inspirepharm.com.
The combination of PARI's LC STAR nebulizer and PRONEB Ultra II compressorprovides for a quick treatment with high efficiency and minimal medicationwaste.
It is hoped that denufosol could be the first early intervention therapyavailable to CF patients that affects an early step in the progression of thedisease. Denufosol for the treatment of cystic fibrosis has been granted FastTrack designation and orphan drug status in the United States by the FDA andorphan drug designation in Europe by the European Medicines Agency (EMEA).
About PARI Respiratory Equipment, Inc.
PARI is a leading worldwide developer and manufacturer of fast andefficient aerosol delivery systems for patients with asthma, chronic lungdisease, and cystic fibrosis. PARI's worldwide vision is to improve the livesof those affected by respiratory diseases and those who care for them.
Maker of the world's leading breath-enhanced reusable nebulizer, the PARILC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufacturersthe award winning PARI TREK S compact compressor, Bubbles the Fish II aerosolmask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valvedholding chamber improves the aerosol deposition of metered dose inhalers(MDIs). PARI's North American headquarters is in Midlothian, VA with worldwideheadquarters in Starnberg, Germany. Online at http://www.Pari.com
SOURCE PARI Respiratory Equipment, Inc.